Welcome to the CellaVision audiocast with teleconference Q2 2021. Today, I am pleased to present CEO Simon Østergaard and CFO Magnus Blixt. For the first half of the call, all participants will be on listen-only mode, so there's no need to mute your individual lines, and afterwards, there'll be a question and answer session. Speakers, please begin. Thank you very much. Thanks a lot. I'm Simon Østergaard, CEO of CellaVision, as you heard, we have Magnus Blixt, our CFO, with us today. First of all, I really appreciate your commitment and dedication to join us today, despite the summer session with quite some alternatives. We'll try not to disappoint you. On the next slide, we have just an outline of CellaVision in short. Essentially, the game plan for today is two parts. We'll have first a section of five, six slides on CellaVision, how we create value, and how CellaVision serves the market. The second part is our Q2 financials that we've launched this morning and that we are presenting now. Finally, we're looking forward to a Q&A session. If we take the next slide. Excellent. Thank you. CellaVision, in brief, we have a vision to become the leader in global digitalization and automation of blood analysis. We're operating in the field of hematology, blood-based analysis. We have built up a leading position within digital cell morphology over the course of two decades. We certainly contribute to improved patient diagnostics and also laboratory workflows, as well as contributing to streamlining and reducing healthcare costs. We have a vision of replacing traditional microscopes in laboratories, and I think it's important to emphasize on the microscope piece. It comes with pre-analytical analysis, so sample preparation, staining protocols, but also sophisticated image analysis, and instruments who can actually magnify what's on the slides of blood. Then we have sophisticated artificial intelligence that helps us interpret what is on the slide. The slide being where we have the blood smeared, which leads us into the opportunity to, as you can see on the photo, you see both red blood cells and the white blood cells in the middle, where they've been stained, and then artificial intelligence and our algorithm is enabling us to actually classify cells and to characterize specific types of white blood cells, red blood cells, platelets, et cetera. That's what we do in a nutshell. We take the next slide. We demonstrate kind of roughly speaking, the market in terms of the major segment that we're serving, which is the large labs. At the large labs, we envision that that's around 17,000 labs. It's labs characterized by doing more than 130 samples per day. Essentially, this population of hospitals and labs are doing 2.5 billion blood samples on an estimate annually, and they go through what's called cell counting and slide smearing and staining systems with our partners that I'll come back to. About one out of seven, approximately 15%, they will be flagged for further analysis, and this is where digital cell morphology comes at play. This is to diagnose diseases like anemia, infections, different types of cancers, leukemia, and myelomas. This is where microscopy analysis is required. You need to stain the cells, and you need to either do it manually or process the slide in the system provided by CellaVision. We believe we have about 20%-25%, so around 22% of the market converted into digital cell morphology, and the remaining part of the market is served by manual microscopy. The large labs are supplemented by also labs defined by smaller sample size. If we take the next slide, we categorize those into medium labs being between 130 and 30 samples per day. You have small labs with a low sample volume per day. We can slice those segments into sub-segments, so labs being part of integrated hospital networks, where the labs are associated and affiliated with other labs across different hospitals or privately as standalone labs. These are very important in the way we view the market and the way we have designed and can utilize our solutions. In this market, as you can see, many more labs, but only 1.5 billion blood samples. You have a low volume that is processed via a vast amount of labs. Again, one out of seven is processed, so the addressable market for our technology will be around 220 million samples. This is again where both processing, the slide smearing and staining comes at play. It's also done manually in this segment before it actually undergoes a digital cell morphology solution. This is the DC-1 product that we earmarked back in 2019 and that we are launching. Of course, COVID has kind of extended the launch, if you like, we are really in the process of learning the segments and selling into the segments. That's an exciting journey. Approximately, the majority, obviously, of the segment is actually still manual, we see this as an attractive market with some of the sub-segments that really caters for our total solution. If we go to the next slide, that shows the overview of the hematology workflow. Here you will see the workflow spelled out between large labs and small labs. In the segment A, for the large labs, we have our big solution, the D M, the DI solutions. In the small lab, on digital cell morphology, we have the DC-1 that I just introduced on the slide before. Briefly speaking, you can say we have different value propositions here. If I had to really emphasize one for the large lab, it's around automation via digitalization, because it really allows us to remove the human variability and errors. That's the attractive part of digitizing the entire workflow, which we've managed to do. For the smaller segments, there are also connectivity is an important value proposition. It actually also goes for the large labs. Connectivity and our Remote Review Software, it allows the user or the owners of the system to work across the integrated hospital labs. It also allows within the standalone labs, because here you can have different lab personnel running the samples and the MD interpreting and doing clinical decision-making in another totally different geography or location. Thirdly, there's the value proposition around controlling the pre-analytical process. That's why we acquired RAL in 2019. Now we are controlling, as you can see on the lower hand bar in the green, we're controlling the smear making, the staining, and the staining protocols with our solutions being RAL branded. This is also introducing reliability, accuracy, and standardization. That's another very pivotal element to really control what comes into the digital cell morphology. In total, we are controlling the green bars, if you like, or the green sub-processes in this chart. We believe this is pretty strong that we are catering for these sub-segments with total full system solutions based on reagents, software, and our hardware solutions. Getting into the next slide, we demonstrate and have outlined the market as we see it from our partners, the partners being the big hematology players who actually are only distributing, but most of them are also serving the hematology market with complete blood counters, cell counters. We go hand in hand with those because our part of the value chain is kind of downstream there. We are pursuing an indirect business model, where we are catering for all the different types of labs in the hematology space via these distributors. We are working closely with our distributors, our distribution partners, I should say, with our profound market support organization. We have our own staff located in 18 markets, and they're covering 40 countries, in fact. We've been undergoing a geographical expansion prior to COVID. You can say on the manufacturing side, in the first part of the value chain, we are also pretty lean. We own all design for all our solutions. However, we have outsourced the assembly of our instruments to a partner here in Sweden. We are doing in-house manufacturing of our reagents out of Bordeaux or Martillac in France. We're a team of 180 employees, the majority in Lund, Sweden. We have a pretty sizable footprint in Martillac, I said, and then we have the market support organization covering these many countries. That's kind of where we are. Let's revisit and let me highlight a few things on the strategic agenda. Next slide, please. On the strategic agenda, I already mentioned the geographical expansion. That's something that we've maintained or we've been intact throughout COVID. There are, obviously, we had the opportunity to look at where to actually expand further. Also, I think we're using a lot of calories on our segment expansion. This is getting the most out of our most recent launch, the DC-1, the value proposition of really serving hospital networks. I'm pleased to say that in that segment expansion where we go to medium-sized labs and smaller labs, I'm pleased to see that the adoption of DC-1 is actually also applicable for the standalone labs. We kind of see a trend of 50/50 between network labs and standalone labs in Europe. Whereas the U.S. is very characterized by networked hospital or hospital networks, which means that the value proposition of DC-1 is actually relatively strong there. The second thing I'd emphasize here is our nimble business model. Both you heard me talk about introducing how we are set up on our streamlined supply chain and also on the commercial operational side on how we've developed our partnerships. It's really a key characteristic of CellaVision, both working with partners across the value chain, but also internally. We strive for simplicity. We're having a lot of focus on also having nimble systems and processes in place. On the partnership model or the components, agenda item number five, I want to stress again that our indirect sales model remains a priority for CellaVision. It is totally unchanged. We have given notice to one of our partners, notice of termination to Mindray in China, so that we will cease working with Mindray as a distribution partner by early 2022. We've seen signals in the market that Mindray is kind of developing its own solution. They really want to compete with our distribution partners by providing the full blood line from CBC all the way to DCM. We're seeing missing strategic alignment here, which is why we've taken this decision. I'll emphasize we have had a busy quarter on innovation. We have acquired the exclusive right to an IP portfolio in April. It's an IP portfolio of FPM, ptychographic microscopy. In technical terms, it's really high magnification images, which can be retrieved with low magnification optics. Essentially, we're able with this technology to extract more insights and more information at a very high speed, but using low magnification optics. In other words, this can actually be a very interesting technology to build, retrieve information, but also build superior workflow solutions, which caters for the workflow across laboratories. It has a promising prospect, which is why we took control of this portfolio, both for as being the high end and the leader within digital cell morphology. We think it's appropriate for us to exploit this, and it could carry a potential in adjacent areas to hematology. We've started feasibility testing, and we are starting to learn sort of strength and limitations from something that is IP to bringing it to real life in the lab. That's pretty exciting. That's one very important component of Q2 outside of the financial. It actually leads me from this intro of our company and a brief statement. It brings me into the financials and the Q2. Let's shift gear and take the next slide, where it starts with second quarter highlights. I think it's there. Yeah. Sales landed at SEK 135.5 million in Q2. We obtained an organic growth of 23%, however, with negative 8% headwind from FX. Essentially 15 points growth. If we kind of dissect our growth of Q2 and look at the different geographies, I'd say Americas was continuing its trend. We grew 66% versus last year, and so we had almost SEK 48 million in Q2. I think it's important to emphasize that it's on a low compare. What we saw last year, what you can also see on the chart to the right if you are online, we had a compare of almost SEK 29 million Q2. What you can't see on the chart, but we actually had a revenue of Q1 2020 of SEK 54.1 million. We really saw a cliff coming from Q1, and then COVID arrived, and we were down to almost half. Then what you've seen throughout the quarters is a gradual, a smooth path of recovery, and we're continuing that trend in Q2 here, landing at SEK 47.7. That's the good news. I think the other good news for America is that we are seeing increased activity. We see that from our conversations with the end users, the laboratories, our opportunity to actually have and attend a first live exhibition. We're seeing things are normalizing. This is extremely important also, as I've talked about the DC-1, a new device for a SOC segment where they have not utilized digital cell morphology. It's extremely important for us to actually have face-to-face interactions. That's good. On the APAC side, we decreased 8%, so we landed at SEK 29.9 million, almost SEK 30 million. It's up against a pretty tough compare, SEK 32.6 million last year. We are still seeing reasonable performance. However, this is the area or the geography where we are still seeing a COVID-19 resurgence. We're seeing positive trends, especially if we zoom in again on the DC-1. This is actually a relatively fragmented market, so this is where we are starting to learn about the different countries, the different markets. We're seeing quite some interest in Indonesia and Australia. We've highlighted that in Indonesia, we see partner interest. We've started to train our partners, and we've been listed on the national e-catalog so that the hospital system can acquire our solution. I think that this is a good improvement. In Australia, we are really training the end users. They are showing interest. They're actually placing orders. The demo of the DC-1 is a poster child example in Australia, where you have these long distances and these hospital networks. We think the full value proposition of DC-1 can really flourish in that part of the world also. In terms of EMEAI, we grew 2%. We landed at SEK 57.8 million. Also in EMEAI, we had a relatively strong compare year. I think it's important, as when we reflect on the beginning of Q2 versus the end of Q2, we believe our market activities and the conditions there have really improved. We're seeing enhanced activity levels and somewhat more flexibility to communicate and interact with the labs, and also to travel in the region. That's really positive. Then as said, on the DC-1, we've also emphasized the fact that we actually see purchase orders coming in also from stand-alone labs. All right. I think we'll hop to the next slide. That contains kind of the other highlights. Here, again, as I said, I think it's expected with a comment around COVID. We see, I know it changes quite a bit across Europe. In general, Europe and Americas, we see activity levels are rising. We are not seeing the same motion across APAC, with some exceptions, as I just mentioned. It's important for us to emphasize that we have not reduced any personnel, and we've had no sizable impact on the supply chain. There is one example that I'll mention a bit later, but that's indirectly due to the pandemic. We are really setting ourselves up to accelerate and continue the healthy trend we have. On DC-1, I've mentioned what I wanted to highlight. I would say, though, for China, we have previously communicated launch of DC-1 in 2021. We have to postpone that. We foresee that that will be next year in 2022, as we have not met the acceptance criteria of a particular electromagnetic compatibility test out in China. That is something that has been accepted elsewhere, so we are identifying root cause and repeating that test, but we do expect some delay. The other thing I want to emphasize is around our reagent distribution. I think it's important to say that our reagent business in RAL is sizable in Europe, and we obviously are at the verge of utilizing our reagents portfolio and capabilities for other regions. APAC is a key region for us, so that's really where we are focused. We have traction in Hong Kong and South Korea, where we have launched. We've registered, evaluated, and launched the products. In China, registration is done, some of our stains, so we expect to launch this year. Across Southeast Asia, we're still doing evaluations of our reagents, and that is really with the purpose of substituting local competitors and getting that certainty from stains of blood cells utilizing the RAL brand. That's an exciting journey of ours. I think on the RAL, it's also worth emphasizing that we had orders worth 3 million SEK that kind of slipped into July, so by then they kind of got out of the quarter. It was due to some shortage of indirect materials, so plastic bottles, cartons, et cetera. You could say non-strategic, however, very much needed. That was due to a kind of a more general supply delay that we've heard across the industry, so there's shortage for our suppliers here. We expect to recover from that and get those orders out in July. That's why the number is actually relatively low there. Otherwise, we are still tracking with mid-single-digit growth, if you adjust from that on the reagent side. On the sales per product group, I'd also emphasize under others, we have our software. We also have spare parts and consumables. On the software side, we've seen kind of significant growth, in particular on our Remote Review. There's a good appetite for Remote Review, which I said previously caters for both the standalone labs, but also the networks, and it goes hand-in-hand with our DC-1 value linked to our larger systems. That's kind of what I wanted to emphasize here. Coming into the next slide, where we actually summarize our P&L. As I said, on top line, we landed the quarter at 23% organic growth with 8% headwind. On the gross margin, we maintained a very healthy gross margin of 69%, equivalent to last quarter, and 3% higher than a year ago. A year ago, as I've emphasized, U.S. was relatively low in Q2. Here we have traction on software, which actually translate into a healthy and a good contribution on our gross margin. On the operating expenses, we're at 41% versus 42% the prior year. It's a little low, and we've done some savings also on sales activities and marketing activities due to still not being ramped up fully. All of this actually translated into the highest EBITDA ever in the history of CellaVision. We landed at 47.1 million SEK. As part of this EBITDA, we also capitalized R&D expenses at SEK 9.3 million versus SEK 6.6 million last year. We have had quite some traction on the R&D programs. On the operating cash flow, healthy, SEK 38.9 million. There I should say that the total cash flow was actually SEK -20 million, if you read the report, and that is primarily due to our FPM acquisition and also dividend payout. The underlying operating cash flow is strong. That's the results of Q2 in a nutshell. The final slide is actually just the historical perspectives from 2016 to 2020. What I just emphasize here is on the chart below, where you see our operating expenses from 2019. You see the dip on the light blue curve. I just want to emphasize kind of what I've also learned here. We at CellaVision have a very nimble model. We are very set up for scalability when we see market dynamics are changing, and given our partnering model that I've talked about or introduced this morning, it kind of demonstrates the scalability of our cost base. I'm pretty pleased with that. I think that's about it. I think it'll be healthy to open up the lines for Q&A. Our first question comes from the line of Ulrik Trattner of Carnegie. Please go ahead. Your line is open. Thank you very much. I have a few questions, if I may. We can perhaps please start off with, if you can help us understand with the underlying gross margins for the different segments. I know you don't report this, but in my books, it looks like gross margin for the sample prep of around 44% and for the rest of the sales around 73.5%. Is that something that sounds about right to you? Just to sort of see the trend on the margin side here. Yeah, I can comment on that, Ulrik. Yeah. It's correct that we have a lower margin on the reagents side. It's a different kind of business where we have the production, versus very high margins on, for example, our softwares where you produce software and then you have a good repeatability on those. In between there, we have the instruments and spare parts and some consumables as well. You are in the right neighborhood when it comes to the margins without being exact on the number. Perfect. Thank you very much, Magnus. Just on sort of rest of the OpEx expenses, and it really looks like sales expenses is down year-over-year or flat to just slightly down year-over-year. What should we expect here going forward? Obviously, it looks like there's been some COVID effects. Should we interpret that as this is something that has sort of limited your commercial expansion, and this should increase going forward, or how should we view this? Yeah. I think in general, our activities on the sales and marketing, so the expenses incurred by our market support organizations, they have been lowered because of less traveling, if any, and also not participating in trade shows, et cetera. We do expect to ramp up those activities. We don't want to hinder, so we don't see it attractive as doing the savings. We would rather do the activities. When we are able to implement these meaningful activities, we will do so again. Okay, great. Just onto sort of increased capitalized expenditure for R&D and product development. It looks like it is pretty high in the quarter. Should this be abating throughout the rest of the year with the finalization of the U.S. study? As we're looking at sort of Chinese approval and Chinese studies right now, that this will be maintained at the same level? As well as you highlight, Simon, during the call that DC-1 approval in China will be pushed to 2022. If you can provide us with any hint of what that means in terms of timing, would it be midyear, second half, or first half of next year when you're expecting the DC-1 to be approved in China? Yeah. The actual approval is kind of out of our hands in terms of timing. We hope that this will be managed in the first part of 2022. Honestly, we see no reason why not, because this is a test that has been conducted in Europe and Americas, elsewhere in history. We think it's about repeatability. I would shoot for the first half. Great. The second question on sort of high capitalized R&D activity here, are we supposed to see this as sort of abating for the second half of this year, or this sort of the maintained level that we should expect? I think that this is what we should probably expect around this level. We certainly find it attractive to, you can say, fuel our innovation pipeline. I think this is a good base to go from, Ulrik. Okay, great. Thanks. Just last question on my end before I get back into the queue. As you highlight, you made an acquisition of an IP portfolio of a novel microscope technology. Could you provide us sort of with how you view this to be integrated into the CellaVision offering, and some hint of a timing when we are to expect a combined or perhaps a novel offering from CellaVision combining this technology or integrating this technology into your complete offering? Yeah. First of all, I think it's extremely important to say that we've acquired the technology, and in its nature, it's a long-term investment. We do believe that the characteristics that it may carry is really, really relevant for a lab environment. It's relevant for hematology, because we believe we can extract more information faster, which means we can translate that into workflow advantages. We're investing in this because we don't just see us as a category leader short term, we see us as the category leader long term in this business. We think it's natural that we supplement our roadmap with these long-term opportunities. There is no doubt that we are balancing. We want to be super focused on maintaining and keeping our position within hematology, but there are opportunities in adjacent areas, as we also said in the press release and in the report. We will share at an appropriate point in time when our feasibility studies, when we've learned more from practicalities, because one thing is an IP on paper, another thing is the engineering effort. That's also why CellaVision acquired this technology, because we not only can have an assessment of the IP, we also have the capability to actually materialize and capitalize on such piece of IP. We're working on feasibility studies and developing, learning this technology from its strength and its weaknesses. At some point in time when we find new applications, we will launch that as we find both appropriate and relevant. That's the game plan. Great. Well, thank you very much, both Simon and Magnus. I'll just get back into the queue. Thanks, Ulrik. Thanks for dialing in and your questions. Thank you. Our next question comes from the line of Carl-Oscar Bredengen of Berenberg. Please go ahead. Your line is open. Morning, everyone. I just wondered if we could touch upon the Mindray distribution agreement, in terms of how this changes the Pan-Asian growth strategy and which other key distributors you have in this area to be successful, and in particular in China, because if I remember, the Mindray one was a strategic partnership with you guys to venture into China. If you can just shed a little bit more light on how you view this Pan-Asian expansion, given the announcement this morning. Yeah. Thanks, Carl-Oscar. Essentially, this doesn't change the market dynamic as to how Mindray or how they compete. They are still competing within the entire blood line. The entire blood line entails both the CBC but also the DC and the digital cell morphology. They're up against our other distribution partners to win the deals of the entire blood cell line. Now they are showing signs that they also want to eventually take control of digital cell morphology. This is why we find ourselves in a situation where we are not strategically aligned anymore because we also have all the other distribution partners that we work with, and we sell CellaVision via those. Mindray will now, I guess, be able to, at some point, launch a solution that competes with the CellaVision. That's how we see it. As you say, Carl-Oscar, it's in China. We don't want to be complacent at all. We take all type of competition. We welcome all types of competition, in fact, because we're on a journey. We're on a journey where we are adopting digital cell morphology. We don't necessarily see it as a bad thing that there are more voices that can demonstrate and persuade the labs to go digital. We're still the high-end solution, and we want to protect that position via a number of activities. We don't think there is any change to that. The strategic alignment of the two companies. They cannot coexist in the ecosystem where we operate. That makes sense. Thank you. You mentioned the DC-1 has been well-received in Australia and Indonesia, and you mentioned that the rollout in EMEA offers a strong value proposition as a standalone instrument to standalone hospitals. Could you shed more light on maybe units sold? You retraced this with your last update. You provided a round number. If you could just maybe give us some quantifiable data here, or maybe just retread what you have previously seen just as a catch-up. Yeah. We're continuing the line of adoption. I think in the last quarter, we saw sales in Q1 equivalent to two quarters of sales of 2020. We are kind of continuing on that trajectory. We don't comment specifically on the number of units, but we are seeing a healthy funnel, double-digit numbers of instruments leaving the door. A month. Is that double instruments leaving the door a month? Yeah. Yeah per quarter. Okay. Per quarter. Just last one on gross profit. That trail that you mentioned towards 69% the last two quarters now versus an average of 66% in Q2 to Q4 in 2020. Is this more the new normal now? Are you seeing sort of increased interest for remote software or add-on software solutions in a COVID and more remote environment? Is this more a seasonal variation? We feel that the gross margin can fluctuate a little bit depending on the product mix. We should not see it as a stable or permanent number. It is true that we see a little bit better adoption of, for example, the software for remote review access also in Europe. We've seen an increase, and we'll see in the future if that will persist or not. It's perhaps a bit too early to say. Okay. Thank you very much. That's all from me for now. Thank you. Thanks, Carl-Oscar. Thank you. Currently, we have one further question in the queue. Just as a reminder to participants, if you do wish to ask a question, please dial zero one on your telephone keypads now. That question comes from the line of Bradley Ware at ABG Sundal Collier. Please go ahead. Your line is open. Thanks. Hi, Simon and Magnus. Congratulations on a solid Q2 result. Thanks. I've just got a couple of questions, please, if I may. The first one is more of an anecdotal one. You comment in the Americas that you attended one live exhibition in June, and then you talk about more live exhibitions in the coming quarter. Could you elaborate on that, please? That kind of demonstrates that we are out there. It's kind of allowed to meet, given the COVID. In the coming quarter, we're really hoping that the AACC, which is the American Association for Clinical Chemistry, it's an annual event, takes place normally, believe it's start August. This year, it'll be at the end of September in Atlanta. That's a major event for the industry and for us at CellaVision as well, because here we have the opportunity to actually really meet both users, but also our distribution partners and their business relationships. It's a very critical event. We hope we're able to be there. We do believe that AACC will run. It will run, actually. Us foreigners coming from the outside of U.S., we are hoping that we will be able to enter the door in the country to join. That's the biggest show, which was canceled last year. We hope that will really take place. On top of that, the Americas team are actually working closely also with our partners on other more local trade shows across the different states. We hope that will also be able to be executed upon now coming into the post-pandemic phase. Okay, great. I just have two other questions, please. I know everyone's touching on this gross margin. You talk about the three factors being product mix, currency, and capitalized expenses. I think, with RAL sales down, are you able to quantify this, for example, the 3% point improvement year-on-year? It seems like given the currency headwind, is it three, four, 5% point improvement from product mix, or how should we understand this, please? It's correct that we've had a currency headwind. A lot of our sales are in euros and dollars, and of course, our reporting currency is in Swedish krona. When the krona is strengthening, then we have a headwind. That's actually negative for our gross margin then. We've achieved the improvement despite the headwind. Okay. I guess it's fair to say FX was a negative contributor to the gross margin this quarter. Yeah was relatively small, the difference must be the product mix, which again, we can see instrument sales and software sales have a much higher margin than RAL products or consumables. Yeah, that is correct. Okay. I can also note here that the capitalized expenses is reflected in our operating expenses and not in the gross profit. That could be excluded from the equation. Yes. Okay. My final question, I apologize in advance for this one, just regarding RAL. I note that sales for the quarter were down. We understand about the postponed order. They're also down for the year. They're lagging the group performance. Can you just perhaps tell us what are the expectations for RAL's financial performance this year and perhaps next year? Yeah. We can see that we've had a fairly stable sales of the RAL products straight through the pandemic. It's more recurring revenue and less sensitive to fluctuations in the market. These reagents, they're sold, and they're needed in upturn and downturn in the financials. We've actually achieved some growth with RAL despite the pandemic then. Looking into the future, it's a little bit hard to say the timing. We can more talk about what we're doing. The important thing for us is that we have a very good traction and a very good reputation around these reagents, these stains in Europe. Our hopes is to copy that and have the same success in the APAC region, but perhaps also in the Americas region. Timing around that is more difficult to say. It's easier for us to talk about the actions and the activities that we do. Hopefully, that will translate into sales in the near future. Okay. Thanks very much. Thank you. As there are no further questions in the call at this time, I'll hand back to our speakers for the closing comments. Again, thanks to all for listening in, despite the season. We're pleased to present some of the key activities, some of the key decisions that we've made throughout Q2. We believe we've come out with a strong Q2 of 23% growth, and organically, with some FX challenges. However, the underlying signals and the indicators point us in the right direction. We are very optimistic about coming out of the unprecedented times and also continuing the journey we're on here at CellaVision. As said, this is my final quarter as the CEO, my first quarter, starting on the 1st of March. Now completing this first quarter, it's been a pleasure working with the team. It's been a pleasure working with the board, and as announced in the CEO comment of our report, as we do work with strategy in a very methodical way, and we are really curious about laying the path forward and continuing the growth journey of CellaVision. With that, I want to again thank you all, and I wish you all a great summer.